TolerogenixX GmbH, a Heidelberg, Germany-based developer of a patented and clinically tested cell therapy technique for individualized immunosuppression in transplant patients, raised seed funding from High-Tech Gründerfonds (HTGF).
The amount of the deal was not disclosed.
Founded at Heidelberg University Hospital and led by Dr. Matthias Schaier, CEO, TolerogenixX develops an individualized immune system in patients through the patented treatment of white blood cells.
The company intends to use the funds to finance preparations for Phase II of the clinical trial, which begins in spring 2018.
Its technique enables the targeted disabling of undesired reactions caused by the immune system’s defences. In a Phase I clinical trial, the technique was employed during kidney transplants. Patients who received transplants became tolerant of the donated organ. Further applications of the technique include the transplantation of other organs and causal treatment of autoimmune diseases.